Abstract:

AIM: To evaluate the clinical effect of Bailing Capsule in children with diabetic renal injury.  METHODS: Forty-eight cases of children with diabetic renal injury were randomly divided into control group and treatment group, 24 cases in each group. On the basis of routine treatment, the control group was given insulin, 0.5 U/kg, 3 times/d, subcutaneous injection; on the basis of the control group, the treatment group was treated with Bailing capsule, 1.0 g/time, 3 times/d, oral. Serum creatinine (SCr), blood urea nitrogen (BUN), beta2 microspheres (beta2-MG), bone morphogenetic protein 7 (BMP-7) and urinary albumin excretion rate (UAER) levels, and efficiency of treatment were compared between groups before and after treatment. RESULTS: After treatment, compared with the control group, the serum levels of SCr, BUN and UAER were lower in the treatment group (P<0.05); the serum level of β2-MG was lower and the serum level of BMP-7 was higher in the treatment group (P<0.05); the treatment efficiency of the treatment group (91.67%) was significantly higher than that of the control group (70.83%), the results were statistically significant. CONCLUSION: Bailing capsule can significantly reduce the serum level of β2-MG and improve the serum level of BMP-7 renal function and clinical efficacy in children with diabetic renal injury.

Key words: Bailing capsule, diabetic renal injury, beta2 microspheres, bone morphogenetic protein-7, clinical efficacy